Researcher awarded grant from Rally Foundation Childhood Cancer Research
The 20/20: Alumni Visionary Grant is part of the Rally Foundation for Childhood Cancer Research's 2026 record-breaking $7 million grant distribution.
Molecular Oncology & Biomarkers
The overall goals of the Molecular Oncology research program are to understand the fundamental cellular and molecular processes that contribute to cancer development and progression.
Normal cells have intricate molecular mechanisms that control essential phenotypes such as differentiation, cell division and movement. The molecular pathways that control these phenotypes are disrupted in cancer cells as a result of the expression of oncogenes and loss of regulatory tumor suppressor genes. These events, which are often highly specific to individual types of cancer, disrupt specific molecular pathways that result in uncontrolled cell growth and loss of normal responses to extracellular signaling cues that result in tumor development and progression.
The research interests of the program can be divided into three broad themes:
- Cancer Genetics
- Epigenetics
- Chaperone Biology
Primary Faculty
- Co-Leader, Molecular Oncology & Biomarker Prog.
- Professor
706-721-8759
Associated Members
Hope M. Amm, PhD
- Assistant Professor
- Assistant Professor
- Professor
- Professor
- Assistant Professor
- Professor
- Professor
- Assistant Professor
- Professor
- Associate Professor
Administrative Staff
Cancer Research News
Young adults with colorectal cancer face delays, unequal access to care
"Social and structural factors play a major role in determining who is diagnosed early, who receives timely treatment and who ultimately survives," says Meng-Han Tsai, PhD.
Gupta selected for prestigious CIMB Travel Award
The CIMB Travel Award is very competitive, with only two winners chosen globally each year.
Revolutionary genome mapping tech targets childhood brain cancers
"We will be able to make a more specific diagnosis, better classify the cancer, give a better prognosis and enable better therapy choices," says Ravindra Kolhe, MD, PhD.